Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.

Antiviral therapy - 1 Jan 2017

Fage Clément, Tu Véronique, Carbonneau Julie, Abed Yacine, Boivin Guy

Abstract excerpt

BACKGROUND: Peramivir is a parenteral neuraminidase inhibitor (NAI) approved for treating influenza infections in a few countries. We determined peramivir susceptibilities of several uncharacterized influenza A and B neuraminidase (NA) and haemagglutinin (HA) mutants selected with different NAIs. METHODS: Recombinant wild-type (WT) and mutant NA proteins were expressed in 293T cells and susceptibility to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclopentanes
Share to Guanidines
Share to Influenza A virus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Influenza B virus

Share to Inhibitory Concentration 50

Share to Neuraminidase

Share to Reassortant Viruses

Share to Viral Proteins

Source

Identifiers

PMID: 29082897
DOI: 10.3851/IMP3158

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.PMID 29082897Read ↗

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceSemantic proximity Read ↗

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.Semantic proximity Read ↗

Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014-2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile.Semantic proximity Read ↗

Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014Semantic proximity Read ↗

Neuraminidase inhibitor resistance in influenza: a clinical perspectiveSemantic proximity Read ↗

In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.Semantic proximity Read ↗

Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.Semantic proximity Read ↗

A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.Semantic proximity Read ↗

Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitorsSemantic proximity Read ↗

[Analysis of the Neuraminidase Amino Acid Sequences of Influenza A/H1N1pdm09, A/H3N2, and B Viruses Isolated from Influenza Patients in the 2013/14 Japanese Influenza Season].Semantic proximity Read ↗

Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.Semantic proximity Read ↗

Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.